Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Wallace, Daniel J;Kalunian, Kenneth;Petri, Michelle A;Strand, Vibeke;Gordon, Caroline;et.al.
(2013) Annals of the Rheumatic Diseases — Vol. 73, n° 1, p. 183-190 (2013)

Files

boreal_122980.pdf
  • Open Access
  • Adobe PDF
  • 2.52 MB
Download

Details

Authors
  • Wallace, Daniel J
    Author
  • Kalunian, Kenneth
    Author
  • Petri, Michelle A
    Author
  • Strand, Vibeke
    Author
  • Houssiau, FrédéricUCLouvain
    Author
  • Gordon, Caroline
    Author
Show more
Abstract
OBJECTIVE: To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE). METHODS: A phase IIb, multicentre, randomised controlled study (NCT00624351) was conducted with 227 patients (37-39 per arm) receiving either: placebo, epratuzumab 200 mg cumulative dose (cd) (100 mg every other week (EOW)), 800 mg cd (400 mg EOW), 2400 mg cd (600 mg weekly), 2400 mg cd (1200 mg EOW), or 3600 mg cd (1800 mg EOW). The primary endpoint (not powered for significance) was the week 12 responder rate measured using a novel composite endpoint, the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA). RESULTS: Proportion of responders was higher in all epratuzumab groups than with placebo (overall treatment effect test p=0.148). Exploratory pairwise analysis demonstrated clinical improvement in patients receiving a cd of 2400 mg epratuzumab (OR for 600 mg weekly vs placebo: 3.2 (95% CI 1.1 to 8.8), nominal p=0.03; OR for 1200 mg EOW vs placebo: 2.6 (0.9 to 7.1), nominal p=0.07). Post-hoc comparison of all 2400 mg cd patients versus placebo found an overall treatment effect (OR=2.9 (1.2 to 7.1), nominal p=0.02). Incidence of adverse events (AEs), serious AEs and infusion reactions was similar between epratuzumab and placebo groups, without decreases in immunoglobulin levels and only partial reduction in B-cell levels. CONCLUSIONS: Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Wallace, D. J., Kalunian, K., Petri, M. A., Strand, V., Houssiau, F., Pike, M., Kilgallen, B., Bongardt, S., Barry, A., Kelley, L., & Gordon, C. (2013). Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases, 73(1), 183-190. https://doi.org/10.1136/annrheumdis-2012-202760 (Original work published 2013)